Trial Profile
A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Nimotuzumab (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 13 Oct 2017 New trial record